Markets are down and IPOs are ice-cold but cell therapies, AI-designed capsids, and 250 active editing trials are sprinting ahead.
To what degree is the biotech ETF likely to be correlated with these advancements (as opposed to them mostly happening in private companies whose value will be priced in long before going public or being added to any index)?
To what degree is the biotech ETF likely to be correlated with these advancements (as opposed to them mostly happening in private companies whose value will be priced in long before going public or being added to any index)?